Trial Profile
CLAU Test Results (CLinical Assessment And Endothelin fUnction Assessment After Endothelin Receptor Antagonist) : Randomized Controlled Clinical Trial of Bosentan for Intermittent Claudication in Peripheral Arterial Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Intermittent claudication; Peripheral arterial disorders
- Focus Proof of concept; Therapeutic Use
- Acronyms CLAU
- 23 Dec 2015 New trial record
- 06 Nov 2015 Primary endpoint of change in flow-mediated arterial dilation (FMAD) respect baseline values has been met, according to results published in the American Journal of Cardiology.
- 06 Nov 2015 Primary endpoint of change in absolute claudication distance (ACD) respect baseline values has been met, according to results published in the American Journal of Cardiology.